Aim: To determine the clinical course, therapy, complications and prognostic factors in patients with VKH disease.
INTRODUCTION
Vogt-Koyanagi-Harada (VKH) disease is a chronic, bilateral, granulomatous panuveitis with extraocular manifestations in the central nervous system, auditory system and integumentary system. 1 The typical clinical manifestations of VKH disease are bilateral panuveitis associated with multifocal serous retinal detachments, central nervous system manifestations in the form of meningismus, headache and cerebrospinal fluid (CSF) pleocytosis, auditory manifestations, such as hearing loss and tinnitus and cutaneous manifestations in the form of vitiligo, alopecia and poliosis. VKH disease consists of four
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phases, namely prodromal, acute uveitic, chronic and chronic recurrent. VKH disease was described independently in 1906 by Vogt, in 1926 by Harada and in 1929 by Koyanagi. The disease has a predilection for more darkly pigmented races. It is distinctly uncommon in whites. 2 Women seem to be more frequently affected than men. Studies in North America reveal that 55 to 78% of those affected are females. 3 Most patients are in their second to fifth decades of life at the onset of the illness. 4 The pathology of VKH disease is basically a granulomatous inflammation throughout the uveal tissues consisting of epitheloid cells, lymphocytes and multinucleated giant cells containing melanin pigment. 5 Evidence suggests that it involves a T-lymphocyte-mediated autoimmune process directed against an antigen associated with melanocytes. 6 The antigen has not been identified. Tyrosinase or tyrosinase-related proteins have been proposed. 7 The principles of therapy of VKH syndrome are to suppress the initial intraocular inflammation with early and aggressive use of systemic corticosteroids, followed by slow tapering over 6 months. Such treatment may shorten the duration of the disease and prevent progression into the chronic stage. 8 The revised diagnostic criteria for VKH disease was drafted at the First International Workshop on VKH disease on October 19th to 21st, 1999, at the University of California, Los Angles, California. 16 The criteria was designed to allow division of VKH disease into complete and incomplete categories, based on the spectrum of manifestations. When the diagnosis was not certain, but the findings highly suggestive, the disease was designated as probable. The prognosis of patients with VKH disease is fair with nearly 60% of patients retaining vision of 20/30 or better. 1 The aim of the study was to determine the clinical course, therapy, complications and prognostic factors in patients with VKH disease that presented to us over 10 years.
MATERIALS AND METHODS
The study was designed as a hospital-based retrospective study. All patients with VKH disease seen at the retina clinic at our hospital between January 1999 and December 2009 were included in the study. The diagnostic criteria included an exudative retinal detachment with typical fluorescein angiographic findings. Patients with a lack of follow-up more than 1 month were excluded. Data was retrieved from the medical records of the patients. Relevant details noted were age and sex of the patient, prodromal symptoms, early or late extraocular manifestations, initial and final best corrected visual acuity (BCVA), cumulative duration of the disease, clinical features of the disease, fundus fluorescein angiographic findings, treatment and complications of the disease. The features studied also included the type of treatment given, response to the initial treatment, number of recurrences, response of recurrence to treatment, chronicity of the disease, type of complications and treatment of complications.
Statistical Analysis
Statistical Analysis was performed using SPSS V.9.05. In order to summarize the data, descriptive statistics, namely mean and percentage were used. For testing the difference between two groups with respect to various factors, the nonparametric test, namely Mann-Whitney test was used, due to lack of normality of the data, (high standard deviation compared to mean). The value of p ≤ 0.05 was taken as the level of significance.
RESULTS
Thirty-eight eyes of 23 patients were included in the study. Of these, 15 patients had bilateral disease. In eight patients, only one eye was affected with the disease as determined clinically and angiographically. There were 17 females (73.91%) and six males (26.08%). The mean age of the patients was 37.26 years (range 15 to 60 years, median 37 years, SD 12.41) ( Table 1 ). The follow-up period ranged from 1 to 96 months (mean 13.73 months, SD 19.75, median 9 months). The chief presenting complaint of all patients was loss of vision in one or both eyes. Patients who had bilateral VKH presented with bilateral symptoms. None of the bilateral cases of VKH presented with unilateral symptoms.
The mean best corrected visual acuity (BCVA) at presentation was 0.73 logMar units ranging from 6/9 to 1/60 (0.2 to 1.8 logMar units). There were no eyes with a visual acuity of 6/6 (0 logMar units) at presentation. Twenty eyes (52.6%) presented with a BCVA between 6/9 and 6/18 (0.2 and 0.5 logMar units).
Ocular findings on slit lamp and fundus examination are shown in Table 2 . All but one eye (37/38) presented with exudative retinal detachment. Twenty-four eyes (64.86%) showed extensive exudative retinal detachment. Thirteen eyes (35.13%) showed multifocal exudative retinal detachment. Eighteen eyes (47.36%) had anterior uveitis. Eleven eyes (28.94%) had cells in the vitreous. Twenty eyes (52.63%) had optic disk edema. The mean intraocular pressure was 12.68 mm Hg (SD 3.58). Fourteen patients (73.68%) presented with bilateral exudative retinal detachment. In the chronic stage, 10 eyes (26.31%) showed sunset glow fundus. None of the patients had Dalen Fuch's nodules or Sugiura's sign. Four eyes (10.52%) had recurrent attacks of anterior uveitis. The mean duration of the first attack of VKH was 5.7 months (SD 11.27). The mean cumulative duration of VKH was 5.78 months (SD 11.27).
Two patients (8.6%) had diabetes mellitus and five patients (21.73%) had hypertension. Prodromal symptoms included headache in nine patients (39.13%), and ocular pain in six patients (26.08%). None of the patients had fever, neck rigidity, tinnitus or hearing loss. One patient (4.3%) had CSF pleocytosis at presentation. Only one patient (4.3%) showed late extraocular manifestations in the form of poliosis, vitiligo and alopecia.
Fundus fluorescein angiography (FFA) was performed in 22 patients (95.65%). Hundred percent of the eyes showed multiple pinpoint hyperfluorescent leaks at the level of the retinal pigment epithelium. Twenty-two eyes (61.11%) revealed staining of the optic disk and 32 eyes (88.88%) showed late accumulation of fluorescein in the subretinal space (Fig. 1 ). Only one patient had an echography done which showed moderate, diffuse low-reflective choroidal thickening with an overlying exudative retinal detachment (Fig. 2) .
All patients were treated with oral prednisolone 1 mg/kg body weight. The mean cumulative duration of systemic corticosteroid therapy was 4 months (SD 2.9, range 1 to 12 months). One patient with profound bilateral loss of vision was treated with intravenous methylprednisolone. Patients with anterior uveitis were treated with topical steroids (15 eyes, 39.47%) and cycloplegic agents (8 eyes, 21.05%). The mean post-treatment BCVA was 0.13 logMar units. There was a statistically significant improvement in visual acuity following treatment (p < 0.05). The visual prognosis of patients with VKH was fairly good following treatment (Table 4) , with 29 eyes (76.31%) achieving a BCVA of 6/6 (0 logMar units), 34 eyes (89.47%) achieving a final visual acuity better than 6/12 (0.3 logMar units) and only one eye (2.6%) achieving 2/60 (1.6 logMar units) vision (see Fig. 3 ). The mean duration of follow-up was 13.73 months (SD 19.75, median 9 months). Thirty-four eyes (89.47%) had a final visual acuity better than 6/12 (0.3 logMar units) (Fig. 3) .
Four patients, 17.39% whose disease was refractory to systemic corticosteroids were treated with Azathioprine, 2.5 mg/kg bodyweight/day in three divided doses. A patient was labeled refractory to treatment, when the clinical improvement was inadequate in terms of resolution of exudative retinal detachment or if there was a recurrence.
Complications of VKH are presented in Table 3 . Eleven eyes (28.94%) showed fundus pigmentry atrophy. Chronic anterior uveitis was seen in four eyes (10.52%). Two eyes (5.26%) had secondary glaucoma, two eyes (5.26%)
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In order to determine factors affecting final visual acuity, patients were divided into two groups: Group A-final BCVA 0 to 0.5 logMar units, (6/6-6/18), group B-final BCVA 0.6 to 1.8 logMar units (6/24-1/60) ( Table 5 ). Nonparametric method, the Mann-Whitney test was used for testing the difference between the two groups. This test was used due to lack of normality of the data since the distribution differed from the normal (high standard deviation compared to mean). The relationship between sex and final visual acuity was tested using the Pearson Chisquare test. p ≤ 0.05 was taken as the level of significance. The factors tested were age, sex, mean pretreatment visual acuity, mean cumulative duration of VKH and mean number of complications.
Better final vision correlated positively with female sex (p < 0.01), better presenting vision (p < 0.05), less number of complications (p < 0.05) and shorter recovery time with treatment (p < 0.01) (Fig. 4) .
DISCUSSION
The main purpose of the study was to determine the clinical course, therapy, complications and prognostic factors in patients with VKH disease.
Female preponderance is evident from our study, as has been reported in literature as well. 1, 9 The mean age of the patients in our study was 37.26 years (range 15-60 years) had prodromal symptoms, including headache, ocular pain, tinnitus, fever and nuchal rigidity.
Fig. 2: B scan: VKH
The uveitis phase quickly follows the prodromal phase with sudden blurring of vision. In our study, 15 patients (65.21%) presented with defective vision in both eyes. Eight patients (34.78%) presented with defective vision in one eye. This compares well with the study by Sugiura S et al 2 who reported blurring of vision in both eyes in 70% of patients. In 30% of patients, there is a delay of 1 to 3 days before the second eye becomes involved. While 47.4% of eyes presented with a visual acuity of less than 6/18, it is heartening to note that the final acuity of 6/6 was achieved in 76.31%, and 89. Hence, in general patients with VKH syndrome who are adequately treated with corticosteroids have a fair visual prognosis with nearly two-third of patients retaining 20/40 or better visual acuity.
1 Table 6 shows a comparative study of the visual prognosis in patients with VKH disease. In our study, 37 (97.36%) eyes presented with exudative retinal detachment. This was comparable with the study done by Rubsamen and Gass 10 which reported 21 (95%) of 22 eyes as having exudative retinal detachment. Only 47.36% in our study had anterior uveitis, while Rubsamen et al 10 reported an incidence of 82%. Likewise, we did not see cells in vitreous cavity in all the cases, although the incidence of disk edema was similar to their report. The convalescent phase, which follows several weeks after the uveitic phase is characterized by depigmentation of the integument and choroid. Depigmentation of the choroid occurs 2 to 3 months after the uveitic phase and is typified by the fundus exhibiting an orange-red discoloration, referred to as sunset-glow fundus. In our study, 10 (26.31%) eyes showed sunset-glow fundus. This appearance is more common in Asian patients than whites. Extraocular signs involving the skin and central nervous system are seen at various stages of the disease. In our study, only one patient (4.3%) showed late extraocular manifestations in the form of poliosis, vitiligo and alopecia in contrast to the study by Beniz J et al 3 which reported vitiligo in 10% of his patients, alopecia in 13% and poliosis in 6%.
In majority of the cases, the diagnosis of VKH is made by clinical examination. Fluorescein angiography (FFA) and echography are useful in substantiating the diagnosis. In our study, all eyes (36 eyes) in which FFA was done showed focal leaks at the RPE level. While disk edema was clinically evident in 20 eyes, two more eyes had evidence of disk involvement on fluorescein angiography.
All our patients were treated with systemic corticosteroids. The mean dose of corticosteroids was 61.05 mg. The mean cumulative duration of corticosteroids was Table 3 ). These results were similar to that reported by Rubsamen and Gass. 10 Corticosteroid therapy for the first episode averaged 6 months. Cumulative steroid therapy averaged 2 years. Sasamoto Y et al 15 reported
decreased anterior chamber inflammation and improved visual acuity after treatment with intravenous methylprednisolone, pulse dose. In our study, four patients (17.39%) who were refractory to systemic corticosteroids were treated with Azathioprine.
Long-term complications in our study were restricted to two eyes (5.26%) each of cataract, secondary glaucoma and subretinal fibrosis. Eleven eyes (28.94%) showed fundus pigmentry atrophy and four eyes (10.52%) developed chronic anterior uveitis. In contrast, Russel Read et al 12 reported cataract in 42% of eyes, glaucoma in 27% of eyes, choroidal neovascular membranes in 11% of eyes and subretinal fibrosis in 6% of eyes.
On univariate analysis, it was found that poor visual acuity at presentation, more number of complications, increased cumulative duration of the disease and male sex were significantly associated with a worse final visual acuity (Table 7) . Similar correlation with presenting vision was reported by Ohno S et al 13 and Russel et al. 12 Russel W Read et al 12 noted that longer duration of the disease and more number of recurrences were significantly associated with a worse final visual acuity. These results were similar to that of our study. The influence of age at presentation on the final vision is controversial. While Russel et al 12 reported
an association with old age, Ohno et al 13 showed an association with young age and in our series, we had no specific association noted.
CONCLUSION
VKH disease is a bilateral, diffuse, granulomatous uveitis associated with vitiligo, poliosis, alopecia, central nervous system and auditory signs. This article presents the clinical features, therapy, complications and prognostic factors in patients with VKH disease. The visual outcomes in this study were far better than that reported in literature. Thirtyfour eyes (89.47%) had a final visual acuity better than 6/12 (0.3 logMar units). Twenty-nine eyes (76.31%) improved to a final visual acuity of 6/6 (0 logMar units).
The incidence of recurrence of the disease after cessation of steroid therapy was very low in our study, when compared to that reported in literature. Most of the patients were managed with oral steroid therapy and we could achieve a good therapeutic outcome. We feel, therefore, there is no necessity to give intravenous methylpredinsolone as a loading dose regimen for VKH disease unless patients present with bilateral profound visual loss. Only a small proportion of patients needed immunnosuppressants, such as Azathioprine in our study. Univariate analysis done to determine factors affecting final visual acuity found that male sex, poor visual acuity at presentation, more number of complications and increased cumulative duration of the disease were significantly associated with a worse final visual acuity. 
